ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2202

The Relationship between Periodontitis and the Treatment Response to Biologics in Rheumatoid Arthritis Patients; A Post-Hoc Analysis Using [18F] Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography

Masahiro Tachibana1,2, Yukio Yonemoto3, Takahito SUTO3, Koichi OKAMURA3, Chisa OKURA3, Hideo SAKANE3 and Hirotaka CHIKUDA3, 1Orthopaedic Surgery, Gunma University Graduate School of Medicine, Maebashi, Japan, 2Orthopedic Surgery, Kiryu Kosei General Hospital, Kiryu, Japan, 3Orthopaedic Surgery, Gunma University Graduate School of Medicine, MAEBASHI, Japan

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Biologics, Periodontitis and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 23, 2018

Title: Imaging of Rheumatic Diseases Poster III: Other Modalities

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:

Rheumatoid arthritis(RA) and periodontitis have been suggested to be related, and they share many clinical and pathologic features. Both diseases are chronic inflammatory diseases characterized by the accumulation and persistence of inflammatory infiltrates in local lesions. Patients with RA are more likely to have periodontitis, and some reports said the treatment response to RA was less in patients with periodontitis than those without periodontitis. However, there has been no report investigating the relationship between the degree of periodontitis and the treatment response to RA. And it is said that [18F] fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) can evaluate both the degree of synovitis of RA and periodontitis.

The aim of this study was to evaluate the relationship between periodontitis and the treatment response to biologics in RA using FDG-PET/CT.

Methods:

Sixty RA patients (14 males, 46 females, average age 58.3(17-80) years) treated with biological therapies were assessed. FDG-PET was performed at baseline and six months after the initiation of biological therapy. The maximum standardized uptake value (SUVmax) was used as a representative value for the assessment of the FDG uptake in periodontal tissue (upper posterior gingival tissue). We also evaluated the DAS28-CRP and several clinical parameters (CRP, ESR, anti-cyclic citrullinated peptide antibody [ACPA], rheumatoid factor [RF], matrix metalloproteinase 3 [MMP-3] ). Wilcoxon’s signed rank sum test and Spearman’s rank correlation test were used to assess the correlation between the periodontal SUVmax and the clinical parameters.

Results:

Periodontal SUVmax at baseline had relation with patient age (r=0.302, p=0.009) and ACPA value (r=0.265, p=0.025).

After biological therapies, the values for DAS28-CRP, CRP, ESR, and MMP-3 were significantly decreased after 6 months. However, the mean periodontal SUVmax increased from 1.83 to 1.88, indicating no significant change in the periodontal SUVmax after treatment. The ACPA and RF values also did not change markedly after treatment. In contrast, we noted a significantly negative correlation between the baseline periodontal SUVmax and the ΔDAS28-CRP (r=-0.369, p=0.004).

Conclusion:

The baseline periodontal SUVmax had a positive correlation with ACPA value. Biological therapies for RA might not cure periodontitis. In addition, concurrent periodontitis might reduce the response to biological therapies in RA patients.


Disclosure: M. Tachibana, None; Y. Yonemoto, None; T. SUTO, None; K. OKAMURA, None; C. OKURA, None; H. SAKANE, None; H. CHIKUDA, None.

To cite this abstract in AMA style:

Tachibana M, Yonemoto Y, SUTO T, OKAMURA K, OKURA C, SAKANE H, CHIKUDA H. The Relationship between Periodontitis and the Treatment Response to Biologics in Rheumatoid Arthritis Patients; A Post-Hoc Analysis Using [18F] Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/the-relationship-between-periodontitis-and-the-treatment-response-to-biologics-in-rheumatoid-arthritis-patients-a-post-hoc-analysis-using-18f-fluorodeoxyglucose-positron-emission-tomography-compute/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-relationship-between-periodontitis-and-the-treatment-response-to-biologics-in-rheumatoid-arthritis-patients-a-post-hoc-analysis-using-18f-fluorodeoxyglucose-positron-emission-tomography-compute/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology